Relates to Heterocyclic compounds of formula (i) where Z1 is c or N L (H) is n, C (H) (R1) or CH2, where R1 is H, amino or hydroxyl Z2 is CR2 or n, where R2 is H or alkyl (C1 - C6) Z3 Z8 and Z9, are each C o n CR4 is Z4 R4 is o n, where h, halogen or alkyl (C1 - C6) Z5 and Z6 is CR5 is n Cr6 or n, where R5 and R6 are each h, halogen, CN, among others Z7 is CR7 o n,Where n is H, halogen, alkoxyl (C1 - C6), among others x1 is cr14r15 or s, where R14 is H, hydroxyl, among others R15 is H, halogen, among others x2 is o, S, N, among others (H) X3 (cr18r19) M or NH, Where M is 0 to 2 R18 is H, alkyl or phenyl (C1 - C6) R19 and R20 each H or alkyl (C 1 - C6) R3 is H, alkyl (c1-c4), amino, among others g is co NH, NH - CH2 - ch2-nh - SO2, co,Among others Q is 0 to 4 r1 is H, halogen, phenyl, among others, R22 is H or alkyl (C1 - C6) Z is phenyl, naphthyl, among others.Preferred compounds are: 1 - [(1 - carbamoyl - 1H indole - 3 - yl) - amide] - 2 - [(pyridin - 3 - methyl) - amide acid] (2S, 4R) - 4 - fluoro - pyrrolidine - 1.2 - dicarboxilico 2 - [1 - (1 - bencilamida - carbamoyl - 1H indole - 3 - yl) - amide acid] (2S, 4R) - 4 - fluoro - pyrrolidine - 1.2 - dicarboxilico among others. It also relates to a Pharmaceutical composition.These compounds are inhibitors of factor D of the alternative complement pathway being useful in the treatment of Macular Degeneration, Diabetic RetinopathySE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE Z1 ES C O N L ES N(H), C(H)(R1) O CH2, EN DONDE R1 ES H, HIDROXILO O AMINO Z2 ES CR2 O N, EN DONDE R2 ES H O ALQUILO(C1-C6) Z3, Z8 Y Z9 SON CADA UNO C O N Z4 ES CR4 O N, EN DONDE R4 ES H, HALOGENO O ALQUILO(C1-C6) Z5 ES CR5 O N Z6 ES CR6 O N, EN DONDE R5 Y R6 SON CADA UNO H, HALOGENO, CN, ENTRE OTROS Z7 ES CR7 O N, EN DONDE R7 ES H, HALOGENO, ALCOXILO(C1-C6), ENTRE OTROS X1 ES CR14R15 O S, EN DONDE R14 ES H, HIDROXILO, ENTRE OTROS R15 ES H, HALOGENO, ENTRE OTROS X2 ES O, S, N(H), ENTRE OTROS X3 ES (CR18R19)m O NH, DONDE m ES DE 0 A 2
